DCGI approves AstraZeneca’s Lynparza for adjuvant treatment of patients with high-risk early breast cancer Read more
CORBEVAX gets EUA from Health Ministry as heterologous COVID-19 booster shot for 18 years and above Read more
SII seeks market authorisation from DCGI for India’s first qHPV vaccine against cervical cancer Read more